摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氨基-1-苯基-1H-吡唑-4-羧酸 | 51649-80-0

中文名称
5-氨基-1-苯基-1H-吡唑-4-羧酸
中文别名
5-氨基-1-苯基吡唑-4-羧酸
英文名称
5-amino-1-phenyl-1H-pyrazole-4-carboxylic acid
英文别名
5-amino-1-phenyl-pyrazole-4-carboxylic acid;5-amino-1-phenylpyrazole-4-carboxylic acid
5-氨基-1-苯基-1H-吡唑-4-羧酸化学式
CAS
51649-80-0
化学式
C10H9N3O2
mdl
MFCD00220607
分子量
203.2
InChiKey
BFMGSMOYBHOHGI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    183-188 °C (dec.)(lit.)
  • 沸点:
    433.8±30.0 °C(Predicted)
  • 密度:
    1.41±0.1 g/cm3(Predicted)
  • 溶解度:
    >30.5 [ug/mL]
  • 稳定性/保质期:

    遵照规定使用和储存,则不会分解。

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    81.1
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • TSCA:
    No
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37
  • 危险类别码:
    R43
  • 海关编码:
    2933199090
  • WGK Germany:
    3
  • 危险标志:
    GHS07
  • 危险性描述:
    H317
  • 危险性防范说明:
    P280

SDS

SDS:9f28cd1c491ca4a588b063e3b2e99532
查看

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid
CAS-No. : 51649-80-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin sensitization (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
May cause sensitization by skin contact.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H317 May cause an allergic skin reaction.
Precautionary statement(s)
P280 Wear protective gloves.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R43 May cause sensitization by skin contact.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37 Wear suitable protective clothing and gloves.
Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C10H9N3O2
Molecular Weight : 203,2 g/mol
Component Concentration
5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid
CAS-No. 51649-80-0 -

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 183 - 188 °C - dec.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,091
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
May cause allergic skin reaction.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes Causes eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Pathak, U. S.; Gandhi, Sudha; Rathod, I. S., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1994, vol. 33, # 8, p. 734 - 737
    摘要:
    DOI:
  • 作为产物:
    描述:
    5-氨基-4-乙氧羰基-1-苯基吡唑 在 sodium hydroxide 、 盐酸 作用下, 以 乙醇 为溶剂, 反应 21.0h, 以85%的产率得到5-氨基-1-苯基-1H-吡唑-4-羧酸
    参考文献:
    名称:
    Synthesis of Pyrazole-Carboxamides and Pyrazole-Carboxylic Acids Derivatives: Simple Methods to Access Powerful Building Blocks
    摘要:
    摘要:含有吡唑基团的混合系统展示了广泛的生物活性。为了获得含有吡唑环的新型混合物,本研究合成了二十种吡唑羧酸和二十种吡唑羧酰胺,采用简单的合成方法,作为开发新结构的基础。
    DOI:
    10.2174/1570178617999200728215322
点击查看最新优质反应信息

文献信息

  • Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors
    作者:Sandra Röhm、Benedict-Tilman Berger、Martin Schröder、Apirat Chaikuad、Rob Winkel、Koen F. W. Hekking、Jorg J. C. Benningshof、Gerhard Müller、Roberta Tesch、Mark Kudolo、Michael Forster、Stefan Laufer、Stefan Knapp
    DOI:10.1021/acs.jmedchem.9b01227
    日期:2019.12.12
    have led to the discovery of several potent inhibitors; however, so far no highly selective type-II inhibitors have been reported. We previously identified VPC-00628 as a potent and selective type-II inhibitor of p38α/β with few off-targets. Here we analyzed the chemical building blocks of VPC-00628 that played a key role in achieving potency and selectivity through targeting an inactive state of the
    p38丝裂原活化的蛋白激酶是环境应激反应的关键介质,并且是治疗炎症性疾病和癌症的有希望的靶标。大量的努力导致发现了几种有效的抑制剂。然而,到目前为止,还没有报道高选择性的II型抑制剂。我们先前将VPC-00628确定为p38α/β的有效且选择性的II型抑制剂,几乎没有脱靶现象。在这里,我们分析了VPC-00628的化学结构单元,这些结构单元通过靶向由独特的折叠P环构象诱导的激酶的非活性状态,在实现效能和选择性方面发挥了关键作用。使用快速,系统的组合合成方法,我们确定了化合物93(SR-318)对p38α/β具有极强的效力和选择性,可有效抑制全血中TNF-α的释放。因此,SR-318提供了一种有效的,选择性的p38α/βII型抑制剂,可用作化学探针,用于靶向这两种p38同工型的特定非活性状态。
  • [EN] PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS<br/>[FR] DÉRIVÉS DE PYRAZOLE-1,2,4-OXADIAZOLE EN TANT QU'AGONISTES DE SPHINGOSINE-1-PHOSPHATE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2010085584A1
    公开(公告)日:2010-07-29
    Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    公开的是Formula (I)或其药学上可接受的盐的化合物,其中:n为零或选自1至4的整数;R1为环烷基、芳基、杂芳基或杂环烷基,每个可选地用从C1到C6烷基、C1到C4卤代烷基、苄基、OR4和/或卤素中独立选择的一个到五个取代基取代;R2、R3、R4和n在此处有定义。还公开了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的,例如自身免疫疾病和血管疾病。
  • [EN] ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ACYLPIPÉRAZINE À TITRE DE BLOQUEURS DE TTX-S
    申请人:RAQUALIA PHARMA INC
    公开号:WO2012020567A1
    公开(公告)日:2012-02-16
    The present invention relates to acyl piperazine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及酰基哌嗪生物,具有阻断电压门控通道(如TTX-S通道)活性的特性,可用于治疗或预防涉及电压门控通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控通道的疾病中使用这些化合物和组合物。
  • Thermal Ring-Opening of Pyrazolo[3,4-<i>d</i> ][1,2,3]triazin-4-ones: An Experimental and Theoretical Study
    作者:Juan P. Colomer、María L. Sciú、Cristina L. Ramirez、Silvia M. Soria-Castro、D. Mariano A. Vera、Elizabeth L. Moyano
    DOI:10.1002/ejoc.201701538
    日期:2018.4.9
    Fil: Colomer, Juan Pablo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnologico Conicet - Cordoba. Instituto de Investigaciones en Fisico-quimica de Cordoba. Universidad Nacional de Cordoba. Facultad de Ciencias Quimicas. Instituto de Investigaciones en Fisico-quimica de Cordoba; Argentina
    尔:科洛默,胡安·巴勃罗。Consejo Nacional de Investigaciones Cientificas y Tecnicas。Centro Cientifico Tecnologico Conicet - 科尔多瓦。Instituto de Investigaciones en Fisico-quimica de Cordoba。科尔多瓦国立大学。Facultad de Ciencias Quimicas。Instituto de Investigaciones en Fisico-quimica de Cordoba;阿根廷
  • Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity
    作者:Hao Liu、Zi-Li Ren、Wei Wang、Jie-Xiu Gong、Ming-Jie Chu、Quan-Wei Ma、Jie-Chun Wang、Xian-Hai Lv
    DOI:10.1016/j.ejmech.2018.07.059
    日期:2018.9
    The identification of novel Topoisomerase II (Topo II) inhibitors is one of the most attractive directions in the field of bactericide research and development. In our ongoing efforts to pursue the class of inhibitors, six series of 70 novel coumarin-pyrazole carboxamide derivatives were designed and synthesized. As a result of the evaluation against four destructive bacteria, including Staphylococcus
    新型拓扑异构酶II(Topo II)抑制剂的鉴定是杀菌剂研究和开发领域中最有吸引力的方向之一。在我们寻求抑制剂的不断努力中,设计并合成了六种系列的70种新的香豆素-吡唑羧酰胺衍生物。作为针对四种破坏性细菌的评估结果,包括黄色葡萄球菌,单核细胞增生性李斯特菌,大肠杆菌和沙门氏菌。与环丙沙星(MIC = 0.5 mg / L)相比,化合物8III-k(MIC = 0.25 mg / L)显示出对大肠杆菌和8V-c的显着抑制活性(MIC = 0.05 mg / L)对沙门氏菌表现出比环丙沙星(MIC = 0.25 mg / L)优异的抗菌活性。所选化合物(8III-k,8V-c和8V-k)表现出对Topo II和Topo IV的有效抑制作用,IC 50值为(9.4-25 mg / L)。分子对接模型表明,化合物8V-c和8V-k可以通过与氨基酸残基相互作用而与靶标良好结合。它将为商业Topo II抑菌剂提供一些有价值的信息。
查看更多